-
公开(公告)号：EP3182993A4
公开(公告)日：2018-01-17
申请号：EP15834421
申请日：2015-08-20
Applicant: PORTOLA PHARM INC
Inventor： WANG JUAN , SACHA GREGORY A , NGUYEN PHUONG M
CPC classification number: C12N9/6432 , A61K9/0019 , A61K9/19 , A61K38/4846 , A61K47/183 , A61K47/26 , C07K14/00 , C12Y304/21006
Abstract: The present disclosure relates to solutions and methods of preparing lyophilized formulations of factor Xa (fXa) antidotes. A suitable aqueous formulation suitable for lyophilization can include a fXa antidote, a solubilizing agent, a stabilizer, and a crystalline component, wherein the formulation does not collapse during lyophilization.
-
公开(公告)号：ZA201701764B
公开(公告)日：2020-10-28
申请号：ZA201701764
申请日：2017-03-10
Applicant: PORTOLA PHARM INC
Inventor： WANG JUAN , SACHA GREGORY A , NGUYEN PHUONG M
Abstract: The present disclosure relates to solutions and methods of preparing lyophilized formulations of factor Xa (fXa) antidotes. A suitable aqueous formulation suitable for lyophilization can include a fXa antidote, a solubilizing agent, a stabilizer, and a crystalline component, wherein the formulation does not collapse during lyophilization.
-
公开(公告)号：AU2015305413A1
公开(公告)日：2017-03-23
申请号：AU2015305413
申请日：2015-08-20
Applicant: PORTOLA PHARM INC
Inventor： WANG JUAN , SACHA GREGORY A , NGUYEN PHUONG M
Abstract: The present disclosure relates to solutions and methods of preparing lyophilized formulations of factor Xa (fXa) antidotes. A suitable aqueous formulation suitable for lyophilization can include a fXa antidote, a solubilizing agent, a stabilizer, and a crystalline component, wherein the formulation does not collapse during lyophilization.
-
公开(公告)号：ES2814157T3
公开(公告)日：2021-03-26
申请号：ES15834421
申请日：2015-08-20
Applicant: PORTOLA PHARM INC
Inventor： WANG JUAN , SACHA GREGORY A , NGUYEN PHUONG M
Abstract: Una formulación acuosa, que comprende de 10 mM a 55 mM de arginina, de 1% a 3% de sacarosa (p/v), de 2% a 8% de manitol (p/v), y al menos 5 mg/ml de un polipéptido bicatenario que comprende una primera cadena que comprende la secuencia de aminoácidos de SEQ ID NO. 4, una segunda cadena que comprende la secuencia de aminoácidos de SEQ ID NO. 5, y un enlace de disulfuro entre un primer resto de cisteína en la posición 98 (Cys98) de SEQ ID NO. 4 y un segundo resto de cisteína en la posición 108 (Cys108) de SEQ ID NO. 5, en la que la formulación tiene un pH de 7,5 a 8.
-
Patent Agency Ranking
公开(公告)号：EA036091B1
公开(公告)日：2020-09-25
申请号：EA201790415
申请日：2015-08-20
Applicant: PORTOLA PHARM INC
Inventor： WANG JUAN , SACHA GREGORY A , NGUYEN PHUONG M
Abstract: Изобретениеотноситсяк воднымсоставамантидотовфактора Xa (fXa) дляпредупрежденияилиуменьшениякровотеченияи способамихполучения, атакжек соответствующимлиофилизированнымкомпозициямдляпредупрежденияилиуменьшениякровотеченияи соответствующимспособам.
-
公开(公告)号：CA2961739C
公开(公告)日：2024-04-30
申请号：CA2961739
申请日：2015-08-20
Applicant: PORTOLA PHARM INC
Inventor： WANG JUAN , SACHA GREGORY A , NGUYEN PHUONG M
Abstract: The present disclosure relates to solutions and methods of preparing lyophilized formulations of factor Xa (fXa) antidotes. A suitable aqueous formulation suitable for lyophilization can include a fXa antidote, a solubilizing agent, a stabilizer, and a crystalline component, wherein the formulation does not collapse during lyophilization.
-
公开(公告)号：DK3182993T3
公开(公告)日：2020-09-21
申请号：DK15834421
申请日：2015-08-20
Applicant: PORTOLA PHARM INC
Inventor： WANG JUAN , NGUYEN PHUONG M , SACHA GREGORY A
-
公开(公告)号：CA2961739A1
公开(公告)日：2016-02-25
申请号：CA2961739
申请日：2015-08-20
Applicant: PORTOLA PHARM INC
Inventor： WANG JUAN , SACHA GREGORY A , NGUYEN PHUONG M
Abstract: The present disclosure relates to solutions and methods of preparing lyophilized formulations of factor Xa (fXa) antidotes. A suitable aqueous formulation suitable for lyophilization can include a fXa antidote, a solubilizing agent, a stabilizer, and a crystalline component, wherein the formulation does not collapse during lyophilization.
-
公开(公告)号：SG11201701247RA
公开(公告)日：2017-03-30
申请号：SG11201701247R
申请日：2015-08-20
Applicant: PORTOLA PHARM INC
Inventor： WANG JUAN , SACHA GREGORY A , NGUYEN PHUONG M
Abstract: The present disclosure relates to solutions and methods of preparing lyophilized formulations of factor Xa (fXa) antidotes. A suitable aqueous formulation suitable for lyophilization can include a fXa antidote, a solubilizing agent, a stabilizer, and a crystalline component, wherein the formulation does not collapse during lyophilization.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.022 seconds)
